Statin adherence and LDL-C reduction in a pediatric population
Autor: | Jens C. Eickhoff, Amy L. Peterson, Connor Enright, Ann Dodge |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
Statin Family education business.industry medicine.drug_class Medication adherence Familial hypercholesterolemia 030204 cardiovascular system & hematology medicine.disease Preventive cardiology 03 medical and health sciences 0302 clinical medicine 030225 pediatrics Internal medicine Pediatrics Perinatology and Child Health medicine lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine business Adverse effect Pediatric population Lipoprotein cholesterol |
Zdroj: | Progress in Pediatric Cardiology. 59:101210 |
ISSN: | 1058-9813 |
Popis: | Statins have demonstrated efficacy and safety in children with primary dyslipidemias such as familial hypercholesterolemia; however, adherence plays a key role in the ability of a statin to lower low-density lipoprotein cholesterol (LDL-C) levels. The objective of this study was to examine the role medication adherence plays in statin efficacy for the treatment of primary and secondary pediatric dyslipidemias. Retrospective review of a pediatric preventive cardiology database identified all subjects 130 mg/dL before beginning a statin. On treatment, 100/131 subjects (76%) met the LDL-C target of ≤130 mg/dL. Of 83 subjects with adherence data available, 61 (73%) met the adherence threshold and the adherent group had significantly greater mean reduction in LDL-C compared to the non-adherent group (−91 mg/dL versus −20 mg/dL, p = .0001). There were no reported adverse effects. These findings indicate that reductions in LDL-C were dependent on medication adherence. Utilizing a model of early intervention, family education, and intensive follow-up to improve adherence may improve clinical outcomes and reduce future ASCVD events in children with primary and secondary dyslipidemias that require lipid-lowering therapy. |
Databáze: | OpenAIRE |
Externí odkaz: |